Research Article

Effects of β-Carotene Supplementation on Molecular Markers of Lung Carcinogenesis in Male Smokers

Margaret E. Wright¹, Steve D. Groshong², Kirsti Husgafvel-Pursiainen³, Erin Genova⁵, M. Scott Lucia³, Henrik Wolff³, Jarmo Virtamo⁴, and Demetrius Albanes⁶

Abstract

Two primary prevention trials unexpectedly showed adverse effects of supplemental β-carotene on lung cancer incidence in cigarette smokers. To elucidate the molecular mechanisms that might underlie these effects, we studied the immunohistochemical expression of cytochrome P450 1A1, 1A2, and 2E1, retinoic acid receptor β, activated protein-1 elements, cyclin D1, and Ki67 in lung tumors and, when available, adjacent normal tissues obtained from incident cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Archival lung tissue was available from 52 men randomized to receive 20 mg of β-carotene per day and 30 men randomized to the placebo arm, all of whom were diagnosed with incident non-small-cell lung carcinoma during the course of the trial and subsequently underwent radical pulmonary resection. In normal-appearing bronchial epithelium, positive staining for cyclin D1 was observed in 23% of cases in the β-carotene group and 0% of cases in the placebo group (based on only 3 of 13 versus 0 of 11 cases staining positively, however; P = 0.04), with no differences in expression noted in lung tumor tissue (P = 0.48). There were no statistically significant differences in Ki67 expression in normal or cancerous lung tissue between intervention groups, although a small increase in staining in tumors was noted among cases in the β-carotene versus placebo group (88% versus 71% of cases stained positive, respectively; P = 0.13). Contrary to expectation, β-carotene supplementation had no apparent effect on retinoic acid receptor-β expression. These findings suggest that male smokers supplemented with β-carotene may have had an increased risk of lung cancer due to aberrant cell growth, although our results are based on a relatively small number of cases and require confirmation in other completed trials of β-carotene supplementation. Cancer Prev Res; 3(6); OF1–8. ©2010 AACR.

Introduction

A vast amount of observational epidemiologic data has accumulated in support of a beneficial association between higher dietary intakes and circulating levels of β-carotene and lung cancer risk (1). Despite this evidence, controlled trials showed either harmful (2–4) or no (5) effects of β-carotene supplementation on lung cancer incidence and mortality. In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, statistically significant increases in lung cancer incidence (16%) and overall mortality (8%) were observed among male smokers randomized to receive 20 mg of supplemental β-carotene daily compared with those that did not receive β-carotene (2, 3). Similar results were obtained from the Beta-Carotene and Retinol Efficacy Trial (CARET), in which men and women randomized to a daily combination of β-carotene (30 mg) and retinyl palmitate (25,000 IU) experienced a 28% increase in lung cancer incidence and a 17% increase in total mortality over those receiving placebo (4). In both trials, the adverse effects were limited to heavier cigarette smokers (3, 6). Although discrepancies between the observational and trial data have been discussed (7, 8), the biological mechanisms underlying these unexpected adverse effects have not been adequately elucidated.

A series of experiments conducted in ferrets have provided the strongest leads to date regarding the observed interactions between β-carotene, cigarette smoking, and lung tumorigenesis. Animals simultaneously fed pharmacologic doses of β-carotene (equivalent to 30 mg/d in humans) and exposed to cigarette smoke for 6 months had increased expression of several phase I carcinogen-metabolizing enzymes, including cytochrome P450s (CYP) 1A1 and 1A2, reduced retinoid signaling due to lower retinoic acid...
concentrations and retinoic acid receptor-β (RAR-β) expression, and increased indicators of cellular proliferation in comparison with animals that were not exposed to β-carotene and cigarette smoke (9–11). To determine whether similar molecular alterations occur in lung tissue in humans, we examined protein expression in a series of non–small-cell lung cancers (NSCLCs) and adjacent normal tissues from smokers who received a β-carotene supplement or placebo for several years in the ATBC Study.

Materials and Methods

Study population

The ATBC Study was a randomized, double-blind, placebo-controlled, primary prevention trial that tested whether daily supplementation with β-carotene (20 mg) and/or vitamin E (50 mg dl-α-tocopheryl acetate) reduced the incidence of lung and other cancers. Details regarding study design, methods, participant characteristics, and compliance have been reported (12). Briefly, 29,133 Finnish male smokers ages 50 to 69 years old and meeting all eligibility criteria were successfully randomized to one of four intervention groups based on the 2 x 2 factorial design (α-tocopherol + β-carotene, α-tocopherol alone, β-carotene alone, or a placebo). The trial ended on April 30, 1993 after 5 to 8 years of active intervention (median 6.1 years). The institutional review boards of both the National Public Health Institute of Finland and the U.S. National Cancer Institute approved the study, and written informed consent was obtained from each participant.

Data collection

Before randomization, all subjects were asked to provide detailed demographic, smoking, and occupational information; give a medical history; complete a 276-item food use questionnaire; and provide an overnight fasting blood sample that was subsequently stored at −70°C until analyzed. A follow-up blood sample was collected at 3 years, and baseline and on-study concentrations of α-tocopherol, β-carotene, and retinol were determined using high-performance liquid chromatography (13).

Case ascertainment

Incident cancers of the lung (International Classification of Diseases-9 code 161) were identified through the Finnish Cancer Registry, which provides close to 100% case ascertainment nationwide (14). Administration of a chest radiograph at baseline ensured that men with apparent lung cancer were excluded from the trial, and periodic chest radiographs taken during the trial and at study exit facilitated ascertainment of lung cancer cases. All relevant medical records were obtained and reviewed independently by two study physicians. Pathology and cytology specimens were evaluated by two pathologists.

We selected a representative sample of trial-period NSCLC cases from the β-carotene alone (n = 52; 70% of all surgical NSCLC cases in this subgroup) and placebo (n = 30; 60% of all surgical NSCLC cases in this subgroup) intervention groups, all of whom underwent surgical resection without prior radiotherapy or chemotherapy, for immunohistochemical study. Formalin-fixed, paraffin-embedded tissue blocks were collected from hospitals where study participants underwent surgical resection. Blocks were then transferred to the Finnish Institute of Occupational Health, where a 4-μm section was cut from each of one to five blocks per case and stained with H&E for pathologic confirmation and assessment of the presence and proportion of tumor (relative to normal) tissue. Blocks containing 30% or more of tumor tissue were selected for this immunohistochemical study, and ten 4-μm consecutive sections were cut from a representative block for each case.

Antibodies and immunohistochemistry

Immunohistochemical procedures for all antibodies except RAR-β were done on the Ventana NexES automated immunostainer platform at 37°C using the I-VIEW (Ventana Medical Systems) enhanced DAB kit with the addition of an Avidin/Biotin Blocking Kit. Negative control serum was either mouse ascites with protein concentration equal to the primary antibody (for Ki67, cyclin D1, and RAR-β) or primary antibody diluent (CYP1A1, CYP1A2, and CYP2E1). CYP1A1, CYP1A2, and CYP2E1: Epitope retrieval (RDI) required enzyme digestion in Pronase (Chemicon/Invitrogen) in PBS (pH 7.6) at 0.5 mg/mL for 7 minutes at room temperature. Antibodies were incubated for 32 minutes (1:1,000 for CYP1A1 and CYP1A2 and 1:75 for CYP2E1). CYP2E1 signal required an Amplifier kit (Ventana). Pancreas islet cells were used as positive controls for all three markers. Ki67: Epitope retrieval (Ventana) was done in a Biocare Decloaker chamber (Biocare Medical) pressure cooker for 5 minutes at 125°C (22 psi). Prediluted Ki67 antibodies were incubated for 28 minutes. Normal tonsil tissue was used as a positive control. Cyclin D1: Sections were retrieved in 10 mmol/L sodium citrate/citric acid buffer (pH 5.8) for 5 minutes in a Biocare Decloaking chamber at 125°C (22 psi) and subsequently incubated for 32 minutes in a prediluted antibody from Ventana; the signal was amplified with a kit containing rabbit anti-mouse heavy and light chains (Amplifier A) and mouse anti-rabbit heavy and light chains (Amplifier B). Breast carcinoma was used as a positive control. Activated protein-1: The activated protein-1 (AP-1) antibody was directed against a COOH-terminal peptide of c-Jun and recognized both the c-Jun homodimer and the c-Jun/c-Fos heterodimer. Working citrate buffer retrieval for 10 minutes in the Decloaker and incubation at 1:100 for 20 minutes were required to detect the AP-1 antigen targeted by the primary antibody (Sigma-Aldrich) in a colon carcinoma control. RAR-β: Antigens to RAR-β (LabVision/ThermoFisher) were retrieved in 10 mmol/L sodium citrate/citric acid buffer (pH 5.8) for 15 minutes in a Biocare Decloaking chamber at 125°C (22 psi). All incubations were done at ambient temperature. Endogenous peroxidase was quenched with 3% aqueous hydrogen peroxide for 10 minutes and the
primary antibody incubation lasted for 30 minutes at a concentration of 1:100. A LabVision UltraVision LP Polymer Detection Kit was used at half strength for detection and incubation for 5 minutes with Cardassian DAB (Biocare) visualized the bound antibody. Colon carcinoma was used as a positive control.

All slides were counterstained with Mayer's hematoxylin for 2 minutes except for those stained for Ki67, which received H&E under a standard method.

After sections were stained with the appropriate antibody and control, two pathologists blinded to the trial intervention assignment were involved in producing the final scores for each specimen and antibody. In each tissue section, three separate “compartments” were analyzed: tumor, normal airways, and normal type I alveolar pneumocytes. Not all slides contained both normal and tumor tissue. Within each compartment, an intensity score between 0 and 3 was assigned to the staining based on evaluation of the entire slide. For percentage staining, random high-power fields (total magnification of ×400) were selected within the specified compartment and 200 cells per sample were counted, scoring each cell as positive or negative. The percentage scores were then binned as described below.

Labeling was restricted to the nuclei for RAR-β, AP-1, Ki67, CYP1A2, and cyclin D1 and to the cytoplasm for CYP1A1 and CYP2E1. Cases that displayed immunostaining in more than 5% of counted cells in a particular target tissue (i.e., tumor, adjacent normal bronchioles, or adjacent normal pneumocytes) were considered as positive in that tissue. The extent of positive staining was categorized as 6% to 20%, 21% to 50%, and >50% of cells; in alternative analyses, we scored expression as positive or negative only. A four-point scale was used to describe the intensity of immunostaining for all markers, except Ki67 and cyclin D1, as follows: 0, negative; 1, weak positivity; 2, moderate positivity; and 3+, strong positivity. An index that integrated both the extent and the intensity of staining was created by summing categorical scores for both measures [maximum possible score: 3 (staining in >50% of cells) + 3 (3+ intensity) = 6].

**Statistical analysis**

Statistical analyses were done using SAS software version 8.02 (SAS Institute, Inc.). For each marker, we compared the extent and the intensity of expression in both tumor and adjacent normal tissues across trial intervention groups. Wilcoxon rank-sum and Fisher’s exact tests were used to examine differences in continuous (extent) and categorical (intensity) staining values, respectively, between the two intervention groups. To determine whether the expression of individual markers differed between tumor and surrounding adjacent normal lung tissues in the same histologic section, we used the Wilcoxon signed-rank test for matched pairs. To address potential confounding, Wilcoxon rank-sum and Fisher’s exact tests were used to test whether several factors, including age, smoking dose and duration, alcohol consumption, body mass index, prerandomization serum nutrient levels, and history of nonmalignant pulmonary disease, differed between the two intervention groups. In addition, correlations between the extent of staining for each marker and the aforementioned covariates were assessed with Spearman correlation coefficients. Stratification of results by lifestyle factors, histologic type (squamous cell carcinoma, adenocarcinoma), intervention time, and baseline serum

| Table 1. Lifestyle and clinical characteristics of lung cancer cases according to trial intervention group |
|-------------------------------------------------|---------------------------------|----------------|
| Age at randomization, y                         | Placebo (n = 30) | β-Carotene (n = 52) | **P** |
| Age at diagnosis, y                            | 62 (56-64)       | 60 (56-65)         | 0.93  |
| Intervention time, d‡                          | 1,689 (601-2,079)| 1,716 (981-2,243) | 0.30  |
| Cigarettes per day at baseline                 | 20 (15-25)       | 20 (19-30)         | 0.55  |
| Years smoked at baseline                       | 41 (38-47)       | 41 (37-45)         | 0.90  |
| Smoking cessation†                              | 5 (17)           | 9 (17)             | 0.95  |
| Alcohol intake at baseline, g/d                | 10.7 (5.5-18.6)  | 10.7 (2.7-34.5)    | 0.71  |
| Baseline serum β-carotene, μg/L§               | 167 (109-282)    | 180 (102-247)      | 0.95  |
| On-study serum β-carotene, μg/L§               | 150 (118-236)    | 2,804 (1,785-3,375)| <0.0001|
| Histology                                      | 14 (47)          | 26 (50)            | 0.81  |
| Squamous cell carcinoma                        | 11 (37)          | 14 (27)            |       |
| Adenocarcinoma                                 | 12 (23)          |                   |       |
| Other                                          | 5 (16)           |                   |       |

NOTE: Data are median (interquartile range) for continuous variables and number (percent) for categorical variables.

*From the Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for categorical variables.

†Time from baseline to last study visit.

‡Defined as having stopped smoking for at least 1 y during the trial.

§Measured 3 y after randomization.
Table 2. Number (percent) of lung cancer cases according to extent of immunostaining for selected markers in tumor and adjacent uninvolved tissue, by trial intervention group

<table>
<thead>
<tr>
<th>Marker</th>
<th>Total cases</th>
<th>Placebo</th>
<th>β-Carotene</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Negative staining</td>
<td>Positive staining</td>
<td>Any positive</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≤5% 6-20% 21-50% &gt;50%</td>
<td>≤5% 6-20% 21-50% &gt;50%</td>
<td>Any positive</td>
</tr>
<tr>
<td>≤5%</td>
<td></td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
</tr>
<tr>
<td>6-20%</td>
<td></td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
</tr>
<tr>
<td>21-50%</td>
<td></td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
</tr>
<tr>
<td>&gt;50%</td>
<td></td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
</tr>
<tr>
<td>Any positive</td>
<td></td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
<td>0 0 0 0</td>
</tr>
</tbody>
</table>

**AP-1**
- Tumor 80 28 (100) 0 0 0 0 49 (94) 0 3 (6) 0 3 (6) 0.97
- Normal bronchioles 25 10 (100) 0 0 0 0 15 (100) 0 0 0 0 0.47
- Normal pneumocytes 37 15 (100) 0 0 0 0 22 (100) 0 0 0 0 0.99

**Cyclin D1**
- Tumor 80 7 (25) 9 (32) 10 (36) 2 (7) 21 (75) 20 (25) 11 (21) 18 (35) 3 (6) 32 (62) 0.48
- Normal bronchioles 24 11 (100) 0 0 0 0 15 (100) 0 0 0 0 0.47
- Normal pneumocytes 30 13 (100) 0 0 0 0 13 (76) 4 (24) 0 0 4 (24) 0.99

**CYP1A1**
- Tumor 79 7 (25) 2 (7) 8 (29) 11 (39) 21 (75) 12 (24) 3 (6) 19 (37) 17 (33) 39 (76) 0.99
- Normal bronchioles 20 7 (70) 0 0 3 (30) 3 (30) 8 (80) 0 0 2 (20) 2 (20) 0.99
- Normal pneumocytes 41 11 (69) 0 3 (19) 2 (13) 5 (31) 20 (80) 1 (4) 2 (8) 2 (8) 5 (20) 0.41

**CYP1A2**
- Tumor 79 0 2 (7) 7 (25) 19 (68) 28 (100) 7 (14) 4 (8) 11 (22) 29 (57) 44 (86) 0.19
- Normal bronchioles 20 2 (29) 0 2 (29) 3 (43) 5 (71) 3 (23) 0 0 10 (77) 10 (77) 0.27
- Normal pneumocytes 41 2 (14) 0 9 (64) 3 (21) 12 (86) 5 (21) 0 16 (67) 3 (13) 19 (79) 0.52

**CYP2E1**
- Tumor 80 1 (4) 1 (4) 4 (14) 22 (79) 27 (96) 10 (19) 3 (6) 11 (21) 28 (54) 42 (81) 0.07
- Normal bronchioles 32 3 (23) 0 0 10 (77) 10 (77) 2 (11) 0 0 17 (89) 18 (89) 0.67
- Normal pneumocytes 51 3 (16) 0 0 16 (84) 16 (84) 2 (6) 0 0 30 (94) 30 (94) 0.89

**Ki67**
- Tumor 79 8 (29) 9 (32) 8 (29) 3 (11) 20 (71) 6 (12) 18 (35) 23 (45) 4 (8) 45 (88) 0.13
- Normal bronchioles 32 13 (83) 1 (7) 0 0 1 (7) 17 (94) 1 (6) 0 0 1 (6) 0.76
- Normal pneumocytes 47 17 (100) 0 0 0 0 30 (100) 0 0 0 0 0.38

**RAR-β**
- Tumor 79 14 (50) 0 5 (18) 9 (32) 14 (50) 22 (43) 5 (10) 9 (18) 15 (29) 29 (57) 0.86
- Normal bronchioles 25 8 (32) 0 0 3 (27) 3 (27) 12 (86) 0 0 2 (14) 2 (14) 0.46
- Normal pneumocytes 42 18 (100) 0 0 0 0 23 (96) 1 (4) 0 0 1 (4) 0.42

*From the Wilcoxon rank-sum test for differences in the extent of marker staining (continuous values) between intervention groups.*
β-carotene concentrations was also done. All reported P values are two-sided.

Results

Characteristics of men diagnosed with lung cancer during the course of the trial and from whom archival lung tissue specimens were collected and analyzed are shown in Table 1 by intervention assignment. There were no significant differences in age at randomization or diagnosis, smoking dose or duration, alcohol consumption, or baseline serum β-carotene concentrations between cases who received the β-carotene supplements and those given placebo. The duration of intervention was also similar in both groups, with most cases participating in the trial for at least 4.5 years before diagnosis. As expected, men in the β-carotene group experienced an approximately 15-fold elevation in serum β-carotene concentrations after 3 years on-study, whereas there was virtually no change in blood concentrations in the placebo group. Squamous cell carcinoma was the most common histologic type in this case series (49%), followed by adenocarcinoma (30%) and other tumor types (21%); this pattern did not differ by intervention assignment.

As expected, the extent of cyclin D1 and Ki67 staining was greater in tumor as compared with normal-appearing pulmonary tissue in both intervention groups (Table 2; all matched-pair P values <0.05). CYP1A1 and CYP1A2 expression were also significantly higher in tumor tissue as compared with normal adjacent pneumocytes (all matched-pair P values < 0.05), but not when compared with normal bronchiolar epithelium. Finally, RAR-β expression was higher in tumor as compared with normal bronchiolar (matched-pair P = 0.02) and normal pneumocytes (matched-pair P < 0.0001) among men randomized to receive the β-carotene supplement, but in placebo group cases, was only greater in tumor versus normal pneumocytes (matched-pair P = 0.02).

Cyclin D1 was expressed in lung tumor tissue in 32 of 52 cases (62%) and 21 of 28 (75%) cases in the β-carotene and placebo groups, respectively (Table 2). Of note was the total absence of cyclin D1 expression in the adjacent normal bronchiolar epithelium in cases randomized to placebo, whereas reactivity was significantly higher in normal bronchioles (P = 0.04) and suggestively higher in normal pneumocytes (P = 0.15) in β-carotene group cases. Ki67 staining was virtually absent in the normal lung tissue, whereas most tumors expressed this proliferation marker, particularly in the β-carotene group [45 of 51 cases (88%) as compared with those in the placebo group, 20 of 28 cases (71%); P = 0.13]. The immunohistochemical staining patterns for cyclin D1 and Ki67 from representative cases with both tumor and adjacent normal tissues present are shown in Figs. 1 and 2.

For CYP1A2 and CYP2E1, there were modest differences between the supplementation groups in the prevalence of positive staining in tumor tissue, with the placebo group showing somewhat greater positivity than the β-carotene group in each instance (P = 0.19 and P = 0.07, respectively). RAR-β was not expressed in normal pneumocytes, was present in a small fraction of normal bronchiolar cells, and was expressed in at least half of the tumor samples, albeit with no differences between the β-carotene and placebo groups.

Results pertaining to the intensity of marker expression corresponded closely with those reported for the extent of positive staining (data not shown). Results from analyses using an index that integrated both parameters were also virtually identical to those reported in Table 2 (data not shown).
To address potential confounding of the aforementioned findings by demographic, lifestyle, and clinical factors, correlations between the extent of staining for each marker and age, smoking intensity and duration, baseline serum antioxidant concentrations, alcohol consumption, body mass index, and history of nonmalignant pulmonary conditions, including asthma, emphysema, and chronic bronchitis, were examined. The majority of markers were not significantly correlated with any of these factors in either tumor or normal tissues (Spearman $P > 0.05$), and none of the covariates examined differed by $\beta$-carotene supplementation status (data not shown).

In analyses stratified by the two primary histologic types of lung cancer, differences in cyclin D1 expression in normal epithelial tissues between intervention groups were only evident in cases diagnosed with adenocarcinoma: 2 of 5 (40%) and 0 of 7 (0%) adenocarcinoma cases showed positive cyclin D1 staining in normal bronchiolar epithelium in the $\beta$-carotene and placebo groups, respectively ($P = 0.06$), and 3 of 8 (38%) and 0 of 8 (0%) normal pneumocytes expressed cyclin D1 in the $\beta$-carotene and placebo groups, respectively ($P = 0.10$). In other stratified analyses, the difference in Ki67 tumor positivity between supplementation groups was apparent only among those cases with a longer trial intervention time (>4.7 years; 93% of cases in the $\beta$-carotene intervention group and 54% of cases in the placebo arm exhibited Ki67 tumor positivity; $P = 0.0009$). No notable effect modification was observed for any of the other markers.

**Discussion**

This investigation is nested within one of a small number of primary lung cancer prevention trials that can examine the biological mechanisms responsible for the adverse effects of long-term $\beta$-carotene supplementation in smokers. Consistent with results from prior animal studies, we found some evidence for more aberrant cell growth in the respiratory epithelium of smokers supplemented with $\beta$-carotene compared with those randomized to placebo. These changes were indicated by modest differences in the expression of cyclin D1 in normal lung tissues between the intervention groups. We also observed somewhat suggestive, yet statistically nonsignificant, increases in Ki67 expression in lung tumors among cases randomized to the $\beta$-carotene versus placebo group. By contrast, $\beta$-carotene supplementation had no effect on RAR-\(\beta\), CYP1A1, or AP-1 expression in our study.

In the only other study to date that has examined similar hypotheses within the context of a randomized supplementation trial, Liu et al. found no significant differences in cyclin D1, proliferating cellular nuclear antigen, RAR-\(\beta\), or CYP1A1 staining in lung tumor tissues from a small subset of $\beta$-carotene versus placebo group cases within the Physicians' Health Study (15). It is important to note that, in contrast to ATBC and CARET, the Physicians' Health Study showed no effect of $\beta$-carotene supplementation on lung cancer incidence (5), and it is therefore not surprising that the immunohistochemical results of Liu et al. were consistent with the main trial finding.

Cyclin D1 is an important regulator of cell cycle progression in normal cells, and its overexpression leads to shortened transition through the G1 phase and uncontrolled growth and proliferation (16). Ki67 is only expressed by proliferating cells and is therefore an established indicator of rapid cell growth (17). Several reports have shown that Ki67 can be detected in the normal-appearing lung tissue of smokers (18–20), and a recent review concluded that Ki67 is an independent predictor of prognosis in NSCLC.

**Fig. 2.** Immunohistochemical localization of Ki67 in normal bronchial epithelium, placebo group (A); normal bronchial epithelium, $\beta$-carotene group (B); lung tumor cells, placebo group (C); and lung tumor cells, $\beta$-carotene group (D). In A and B, nuclear positivity for Ki67 is essentially absent in columnar ciliated bronchiolar-type epithelium. In C, only scattered malignant cells show nuclear staining for Ki67, whereas numerous positive-staining nuclei are apparent in D. Rare scattered inflammatory cells are also positive for Ki67 in D. All photomicrographs are at $\times20$ magnification.
because proliferation is a direct result of more rapid progression through the cell cycle, we expected concordant staining between the two markers, which has been previously reported (22). Instead, we found that compared with the placebo group, men receiving β-carotene had higher expression of cyclin D1, but not Ki67, in normal-appearing lung epithelium and slightly higher expression of Ki67, but not cyclin D1, in malignant tissue. Of note was our finding that only 6% of cases exhibited positive Ki67 immunostaining in the normal bronchiolar lung tissue, which is low when compared with several previous reports (18–20). Although this discrepancy may be attributed to our threshold for positive Ki67 immunostaining—greater than 5% of counted cells in a particular target tissue—lowering the cutoff point to >3% of cells staining positive yielded nearly identical results. The discordance between cyclin D1 and Ki67 staining suggests that negative regulators of cyclin D1, such as cyclin-dependent kinase inhibitors (including the INK4 and Cip/Kip families of proteins; ref. 23), may be active in lung tumor tissue, and that malignant cells are proliferating in a cyclin D1–independent manner. Additional evaluation of cyclin-dependent kinase inhibitors such as p21CIP1 and p27KIP1 would be highly informative in this regard. Alternatively, overexpression of cyclin D1 may be influencing processes unrelated to proliferation, or our findings could be due to chance.

In contrast to animal studies that showed diminished retinoid signaling—confirmed by decreases in the expression of RAR-β and upregulation of downstream targets, including AP-1—and increased expression of CYP1A1 and CYP1A2 in ferrets supplemented with β-carotene and simultaneously exposed to tobacco smoke (10, 11), we did not observe an effect of β-carotene supplementation on RAR-β, AP-1, or CYP1A1 expression in the lungs of male smokers. Although we found that expression of CYP1A2 in lung tumor tissues was suggestively lower in β-carotene supplemented versus placebo cases, these differences were not statistically significant. These discrepancies could be due to subtle biological and anatomic differences between the two species and/or differences in study procedures, including specific antibodies used and route of administration of the carcinogenic agents. For example, whereas the entire ferret lung was exposed to tobacco smoke, yielding peripheral alveolar changes, cigarette smoke concentrates in the central airways in humans. Importantly, none of the ferrets in any exposure group developed lung tumors, although some developed squamous metaplasia (11), a lesion common in the bronchi of smokers. Differences could also be due to the fact that all ATBC Study participants were smokers, whereas smoke-exposed and non–smoke-exposed ferrets with or without β-carotene supplementation were evaluated in aforementioned experiments.

Loss of expression of RAR-β, a nuclear receptor that mediates the effects of retinoic acid on normal epithelial cell growth and differentiation, is a common event in lung cancer precursor lesions and overt tumors (24–27), and is often ascribed to promoter methylation (28). Contrary to expectation, we observed that RAR-β was upregulated in lung tumors as compared with normal adjacent tissue. This may be explained by the failure of our antibody to distinguish between the different RAR-β isoforms; this could be important because the β4 form seems to be oncogenic whereas the β2 variant acts as a tumor suppressor (26).

Our study benefited from the availability and examination of both lung tumor and adjacent normal tissue in many of the cases, although histologically normal-appearing epithelial cells may not actually be truly normal due to field carcinization (29). The small sample size may have restricted our ability to detect modest, yet significant, differences in protein expression between the β-carotene and placebo groups; in a similar vein, all stratified analyses were considered completely exploratory. Also, a comparison group supplemented with β-carotene but not having lung cancer (e.g., from a bronchoscopy series) could have been informative but was not available for study. The semiquantitative nature of the immunohistochemical techniques used in our study is a known limitation (30, 31). Finally, paraffin-embedded tissue sections may show diminished immunoreactivity over time, which could lead to false-negative staining (32). In our study, decreased antigenicity due to extended storage could, for example, have masked subtle differences in Ki67 staining in the normal bronchial epithelium between trial intervention groups.

In summary, our findings indicate that the higher lung cancer rates observed in smokers randomized to receive supplemental β-carotene in two separate clinical trials may have been due to aberrant cell growth in the respiratory epithelium of these individuals, although our findings certainly require confirmation in CARET or other completed trials of β-carotene supplementation. Importantly, most of the molecular markers dysregulated by the combination of exposure to tobacco smoke and β-carotene supplementation in animal experiments, including RAR-β, were not similarly altered in our investigation. Identification of additional molecular markers of the adverse β-carotene effect on lung carcinogenesis is warranted.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Dr. Anna Kannio and Tuula Suitiala for formalin-fixed, paraffin-embedded lung tissue preparation and quality control.

Grant Support

Intramural Research Program of the National Cancer Institute, NIH.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 06/02/2009; revised 01/13/2010; accepted 01/27/2010; published OnlineFirst 05/18/2010.
References

Effects of β-Carotene Supplementation on Molecular Markers of Lung Carcinogenesis in Male Smokers

Margaret E. Wright, Steve D. Groshong, Kirsti Husgafvel-Pursiainen, et al.

Cancer Prev Res Published OnlineFirst May 18, 2010.

Updated version Access the most recent version of this article at: doi:10.1158/1940-6207.CAPR-09-0107

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.